Albumin-Based Liver Reserve Models vs. MELD 3.0 in Prognostic Prediction for Hepatocellular Carcinoma Patients with Renal Insufficiency
International Journal of Molecular Sciences · 30.11.2023 · 24 (23) · 16987
DOI: 10.3390/ijms242316987 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 30.11.2023. Verfasst von Shu-Yein Ho und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology and Hepatology, Min-Sheng General Hospital, Taoyuan 33044, Taiwan. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Renal Insufficiency. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDDK NIH HHS, Taipei Veterans General Hospital.
Abstract (Originalsprache)
The severity of liver functional reserve is an important prognostic predictor in hepatocellular carcinoma (HCC). The albumin–bilirubin (ALBI), easy (EZ)-ALBI, platelet-albumin–bilirubin (PALBI), platelet–albumin (PAL) score, and MELD 3.0 score are used to evaluate the severity of liver dysfunction. However, their prognostic role in HCC patients, specifically with renal insufficiency (RI), is unclear. We aimed to investigate the predictive accuracy of the five models in these patients. A total of 1120 newly diagnosed HCC patients with RI were enrolled. A multivariate Cox proportional analysis was used to identify independent predictors associated with survival. In the Cox model, older age, an α-fetoprotein ≥20 ng/mL, vascular invasion, a medium and high tumor burden score, poor performance status, a higher ALBI grade, an EZ-ALBI grade, a PALBI grade, a PAL grade, and MELD 3.0 score were all independently associated with decreased overall survival (all p < 0.001). Among the five liver reserve models, the ALBI grade is the best surrogate marker to represent liver functional reserve in terms of outcome prediction. The albumin-based liver reserve models (ALBI, EZ-ALBI, PALBI, and PAL) and MELD 3.0 are all feasible prognostic markers to indicate liver injury, specifically in HCC patients with RI. Among them, the ALBI grade is the most robust tool for survival prediction in these patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Gastroenterology and Hepatology, Min-Sheng General Hospital, Taoyuan 33044, Taiwan.
- School of Medicine, National Yang Ming Chiao Tung University, Taipei 11221, Taiwan.
- Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
- VA Sierra Nevada Health Care System, Reno, NV 89502, USA.
- Department of Medicine, Taipei Veterans General Hospital, Taipei 11217, Taiwan.
- Healthcare & Services Center, Taipei Veterans General Hospital, Taipei 11217, Taiwan.
ORCID-Profile: Yi-Hsiang Huang, Chien-Wei Su, Teh-Ia Huo
Förderung
- NIDDK NIH HHS
- Taipei Veterans General Hospital
Zitieren
APA
Ho, S. Y., Liu, P. H., Hsu, C. Y., Tseng, H. T., Huang, Y. H., Su, C. W., Hou, M. C., & Huo, T. I. (2023). Albumin-Based Liver Reserve Models vs. MELD 3.0 in Prognostic Prediction for Hepatocellular Carcinoma Patients with Renal Insufficiency. International Journal of Molecular Sciences, 24(23), 16987. https://doi.org/10.3390/ijms242316987
Vancouver
Ho SY, Liu PH, Hsu CY, Tseng HT, Huang YH, Su CW, et al. Albumin-Based Liver Reserve Models vs. MELD 3.0 in Prognostic Prediction for Hepatocellular Carcinoma Patients with Renal Insufficiency. International Journal of Molecular Sciences. 2023;24(23):16987. doi:10.3390/ijms242316987
BibTeX
@article{Ho2023,
author = {Ho, Shu-Yein and Liu, Po-Hong and Hsu, Chia-Yang and Tseng, Hung-Ting and Huang, Yi-Hsiang and Su, Chien-Wei and Hou, Ming-Chih and Huo, Teh-Ia},
title = {Albumin-Based Liver Reserve Models vs. MELD 3.0 in Prognostic Prediction for Hepatocellular Carcinoma Patients with Renal Insufficiency},
journal = {International Journal of Molecular Sciences},
year = {2023},
volume = {24},
number = {23},
pages = {16987},
doi = {10.3390/ijms242316987}
}
EUVIMED